Stephens & Co. Downgrades Lifecore Biomedical to Equal-Weight, Lowers Price Target to $2
Stephens & Co. Downgrades Lifecore Biomedical to Equal-Weight, Lowers Price Target to $2
Stephens & Co.将Lifecore Biomedical的评级下调至同等权重，将目标价下调至
Stephens & Co. analyst Jacob Johnson downgrades Lifecore Biomedical (NASDAQ:LFCR) from Overweight to Equal-Weight and lowers the price target from $11 to $2.
Stephens & Co. 分析师雅各布·约翰逊将Lifecore Biomedical（纳斯达克股票代码：LFCR）的评级从增持下调至同等权重，并将目标股价从11美元下调至2美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。